Who are EU-approved Cosentyx's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taltz, Cosentyx, Secukinumab 150 milligram [Cosentyx], Subcutaneous injection of Secukinumab, Vunakizumab (IL-17A inhibitor), Secukinumab Auto-Injector.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eu-approved-cosentyx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

EU-approved Cosentyx — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EU-approved Cosentyx (EU-approved Cosentyx) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-17A inhibitor (monoclonal antibody). Area: Immunology / Dermatology / Rheumatology.

phase 3 IL-17A inhibitor (monoclonal antibody) IL-17A Immunology / Dermatology / Rheumatology Biologic Live · refreshed every 30 min

Target snapshot

EU-approved Cosentyx (EU-approved Cosentyx) — Celltrion. Cosentyx is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated skin and joint diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
EU-approved Cosentyx TARGET	EU-approved Cosentyx	Celltrion	phase 3	IL-17A inhibitor (monoclonal antibody)	IL-17A
Taltz	ixekizumab	Eli Lilly	marketed	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	marketed	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Secukinumab 150 milligram [Cosentyx]	Secukinumab 150 milligram [Cosentyx]	Professor Mikkel Østergaard	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Subcutaneous injection of Secukinumab	Subcutaneous injection of Secukinumab	Peking Union Medical College	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A (Interleukin-17A)
Vunakizumab (IL-17A inhibitor)	Vunakizumab (IL-17A inhibitor)	Fujian Cancer Hospital	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Secukinumab Auto-Injector	Secukinumab Auto-Injector	University of Pennsylvania	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-17A inhibitor (monoclonal antibody) class)

Eli Lilly and Company · 2 drugs in this class
Celltrion · 1 drug in this class
Biocad · 1 drug in this class
Peking Union Medical College · 1 drug in this class
Professor Mikkel Østergaard · 1 drug in this class
University of Pennsylvania · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EU-approved Cosentyx — Competitive Intelligence Brief. https://druglandscape.com/ci/eu-approved-cosentyx. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing